Dementia | TB006

Dr. Sikora is proud to announce that the office is participating in an Expanded Access Program offered by the drug manufacturer.

True Binding TB006 for Alzheimer’s Treatment

TB006 is a medication that is listed by FDA as compassionate use as an investigational medical drug for treatment of Alzheimer’s. The medication is delivered via IV and is currently recommended to be administered at least once per year but preferable once a month for 4 months and then interval at an interval determined individually.

TB006 is a monoclonal antibody that binds to a protein called galectin-3 and removes this protein from circulation. Galectin-3 is bound to amyloid beta proteins. The amyloid proteins form plaques that is impairs neurons from communicating properly. Removal of the Galectin-3/amyloid-beta plaques helps neurons return to normal function.

The medication is being offered in this capacity because no other medication is available in this category. The FDA is monitoring for serious side effects and adverse reactions. There have been no significant side effects reported with delivery of medication compared to other therapies that have risk of cerebral edema and hemorrhage.

Phase 1b/2 trial results showed significant improvement. See links below for results.

Regenerative Medicine

Contact us for more Information

Requirements

Diagnosis of Alzheimer
Mini Mental Status Exam of 25 or less
Failed other medications for Alzheimer’s (ie Exelon, Aricept, Namenda)

For More Information

www.truebinding.com
TrueBinding-Topline-Release
TB006, a potentially revolutionary antibody drug for Alzheimer’s Diseases – Video
3 months of TB006 eased, reversed signs of Alzheimer’s disease: Trial

How Much Does TB006 Cost?

Please note that no insurance is covering TB006 at this time. The cost is $4900 for a treatment. Physical exam and labs must be done prior to the treatment. At this stage, TB006 is experimental and still undergoing clinical trials. If you decide to partake in the program, you will need to cover the following costs:

Manufacturing costs: TB006 is expensive to manufacture. You will need to cover all costs related to producing the medication, which have been approved by the FDA.
Physician fees: Patients on the EAP will need to cover physician and doctor fees. These cover the cost of your medical care as charged by the clinic.
Assessment charges: You’ll also need to pay for any costs associated with laboratory testing and symptom assessments to monitor treatment progress.

Is TB006 Worth the Cost?

Whether the TB006 Expanded Access Program is worth the cost depends on who you ask and your unique financial situation. Many believe the following benefits of TB006 justify the expense:

TB006 Alzheimer is one of the only drugs that targets one of the causes of Alzheimer’s disease. It binds to a protein called Galectin-3, which helps prevent toxic protein build-ups (amyloid plaques) from forming in the brain.
TB006 not only slows the progression of Alzheimer’s—it has the potential to reverse the disease. In a clinical trial, half of patients given TB006 for three months had a reversal of symptoms and improved memory and cognition.
As TB006 has the potential to reverse Alzheimer’s, it’s a one-of-its-kind treatment. It can transform the lives of patients and their loved ones.

Other Alzheimer’s Drugs

Although TB006 is expensive, its price is more easily justified when considering the cost of its competitors, Lequembi and Aduhelm.

These are the only two FDA-approved drugs that, like TB006, target the causes of Alzheimer’s disease.

Leqembi costs $26,500 per year, which is out of pocket for many Alzheimer’s patients. According to the Institute for Clinical and Economic Review (a group that helps determine a fair price for new medication), this is overpriced. They suggested an appropriate cost of $8,500 to $20,600 annually.

However, it’s more affordable than Aduhelm. According to NBC News, this drug was approved in 2021 and was priced at $56,000 per year.

With almost 7 million Americans living with Alzheimer’s disease, this is disappointing news for many patients and their loved ones.